NIDA (National Institute on Drug Abuse) supported basic and clinical research which led to the development of buprenorphine. These scientific discoveries spurred a collaboration with industry, which culminated in FDA approval of Subutex® (buprenorphine) and Suboxone® tablets (buprenorphine/ naloxone) in October 2002.
Buprenorphine sublingual preparations are often used in the management of opioid dependence (that is, dependence on heroin, oxycodone, hydrocodone, morphine, oxymorphone, fentanyl or other opioids). It is a long-acting partial mu opiate agonist that acts on the receptor targets of heroin and morphine, but does not produce the same intense "high" or dangerous side effects. These properties also make it a good potential treatment for addiction to opiate analgesics.
The use of Medication assisted treatment in the management of opioid dependence is highly regulated, owing to the sometimes controversial nature of this aspect of harm reduction policy. In the United States, a special federal waiver is required to prescribe Subutex and Suboxone for opioid addiction treatment on an outpatient basis.
Weyland Consultation Services is licensed for the use buprenorphine products and has developed strategies that minimize the diversion liability of opiate medications. Their drug addiction programs have demonstrated a robust effect in reducing opiate use and drug cravings in heroine abusers and have confirmed its safety.
Buprenorphine's unique formulation with naloxone, an opioid antagonist (Suboxone), limits diversion by causing severe withdrawal symptoms in those who inject it to get "high", but no adverse effects when taken orally (naloxone is minimally absorbed when taken orally). This exemplifies the feasibility of developing strategies that minimize the diversion liability of opiate medications.
Weyland found that buprenorphine demonstrated a robust effect in reducing opiate use and drug cravings in heroine abusers and has confirmed its safety.
Weyland Consultation Services specializes in designing outpatient treatment programs that address the values and beliefs of the people they serve, thereby increasing their ability to engage and participate as active collaborants in their treatment. They offer a gender specific drug treatment programs that gives the drug abuser a viable outpatient opportunity to attain recovery. These outpatient services are provided in a calm and soothing environment that is discreet while supporting the patient's efforts to take the risk to the necessary steps toward ongoing recovery at the patients pace.
If you want more information about Opioid Drug Treatment Programs utilizing Buprenorphine for its effect in reducing opiate use and drug cravings in heroine abusers and reside in the Northern California, San Francisco Bay Area - Oakland, Berkley, Danville, Concord and Walnut Creek areas - visit their website www.WeylandDetoxServices.com/ or call (925) 945-7816 ext. 41.
